First author | Design | Year | Country | Population | Infection type—bacteria | No. of screened | No. of ESBL-PE BSIs (%) | No. of BSIs caused death | No. of ESBL-PE BSIs caused death (%) | ESBL detection method |
---|---|---|---|---|---|---|---|---|---|---|
ESBL-PE only | ||||||||||
Wang [31] | MC retrospective cohort | 2011 | Taiwan, China | Adults with solid or hematological malignancy | E. coli and Klebsiella | 351 | 113 (32.2%) | 35 | 35 (31.0%) | MicroScan |
Wu [15] | SC prospective cohort | 2012 | Taiwan, China | Adults with solid or hematological malignancy | E. coli | 97 | 39 (40.2%) | 10 | 10 (25.6%) | Disk diffusion |
Kang [17] | MC retrospective cohort | 2013 | Korea | Adults with solid malignancy | E. coli | 92 | 36 (39.1%) | 6 | 6 (16.7%) | Microdilution or disk diffusion |
Gudiol [29] | MC retrospective cohort | 2017 | Spain | Adults with acute leukemia and neutropenia | E. coli, Klebsiella, and Enterobacter cloacae | NR | 425 | 65 | 65 (15.3%) | Disk diffusion |
Cattaneo [23] | MC prospective cohort | 2018 | Germany | Adults with hematological malignancy | E. coli, Klebsiella, and other Enterobacter spp | 137 | 61 (44.5%) | 10 | 10 (16.4%) | Microdilution |
Benanti [32] | SC retrospective cohort | 2019 | USA | Adults with hematological malignancy | E. coli | NR | 103 | 11 | 11 (10.7%) | NR |
ESBL-PE and non-ESBL-PE | ||||||||||
Trecarichi [13] | SC retrospective cohort | 2009 | Italy | Adults and children with hematological malignancy | E. coli | 107 | 26 (24.3%) | 13 | 11 (42.3%) | Disk diffusion |
Gudiol [27] | SC prospective cohort | 2010 | Spain | Adults and children with solid or hematological malignancy | E. coli | 531 | 17 (3.2%) | 29 | 6 (35.3%) | MicroScan |
Cornejo-Juarez [40] | Case–control study | 2012 | Mexico | Adults and children with hematological malignancy | E. coli | 670 | 100 (14.9%) | 102 | 51 (51%) | MicroScan |
Kang [14] | MC retrospective cohort | 2012 | Korea | Adults with hematological malignancy | E. coli and Klebsiella | 142 | 29 (20.4%) | 29 | 13 (44.8%) | Microdilution or disk diffusion |
Ha [16] | SC retrospective cohort | 2013 | Korea | Adults with solid or hematological malignancy | E. coli | 350 | 95 (27.1%) | 52 | 21 (22.1%) | Disk diffusion |
Kim [18] | SC retrospective cohort | 2013 | Korea | Adults with hematological malignancy and FN | E. coli and Klebsiella | 96 | 23 (24.0%) | 8 | 4 (17.4%) | MicroScan |
Metan [34] | SC retrospective cohort | 2013 | Turkey | Adults and children with hematological malignancy | E. coli, Klebsiella, and Enterobacter cloacae | 154 | 40 (26.0%) | 30 | 5 (12.5%) | NR |
Bodro [19] | SC prospective cohort | 2014 | Spain | Adults with solid or hematological malignancy | Klebsiella and other Enterobacter spp | 392 | 19 (4.8%) | 18 | 4 (21.1%) | Disk diffusion |
Kim [28] | SC prospective cohort | 2014 | Korea | Adults and children with solid or hematological malignancy | Enterobacter spp | 203 | 31 (15.3%) | 34 | 6 (19.4%) | Disk diffusion |
Han [20] | SC retrospective cohort | 2015 | Korea | Children with solid or hematological malignancy and FN | E. coli and Klebsiella | 59 | 21 (35.6%) | 3 | 1 (4.8%) | VITEK®2 automated system |
Cattaneo [21] | MC prospective cohort | 2016 | Italy | Adults with acute leukaemia | Enterobacter spp | 433 | 36 (8.3%) | 37 | 5 (13.9%) | Microdilution or disk diffusion |
Ma [22] | SC retrospective cohort | 2017 | China | Adults with hematological malignancy | E. coli | 168 | 97 (57.7%) | 21 | 15 (15.5%) | Disk diffusion |
Çeken [24] | SC retrospective cohort | 2018 | Turkey | Adults with solid or hematological malignancy | E. coli and Klebsiella | 122 | 70 (57.4%) | 31 | 23 (32.9%) | VITEK®2 automated system |
Islas-Muñoz [25] | SC prospective cohort | 2018 | Mexico | Adults with solid or hematological malignancy | E. coli, Klebsiella, and Enterobacter spp | 496 | 123 (24.8%) | 89 | 37 (30.1%) | Disk diffusion |
Ben-Chetrit [42] | SC retrospective cohort | 2019 | Israel | Adults with solid or hematological malignancy | E. coli and Klebsiella | 88 | 26 (19.5%) | 17 | 6 (7.5%) | NR |
Isendahl [26] | Case–control study | 2019 | Sweden | Adults and children with solid or hematological malignancy | E. coli and Klebsiella | 945 | 238 (25.2%) | 107 | 45 (18.9%) | NR |
Kim [35] | SC prospective cohort | 2019 | Korea | Adults with solid or hematological malignancy and FN | E. coli and Klebsiella | 179 | 23 (12.8%) | 51 | 8 (34.8%) | MicroScan |
Namikawa [30] | Case–control study | 2019 | Japan | Adults with solid or hematological malignancy | E. coli, Klebsiella, and Enterobacter spp | 65 | 42 (64.6%) | 13 | 9 (21.4%) | NR |
Zhang [33] | SC retrospective cohort | 2019 | China | Adults with solid or hematological malignancy | E. coli | 324 | 160 (49.3%) | 71 | 39 (24.4%) | VITEK®2 automated system |